Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 5/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015140 | 1.00 | ADORA1 (0.55) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL12590069 | 1.00 | ADORA1 (0.55) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL18058950 | 0.93 | ADORA1 (0.53) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL19884372 | 0.92 | ADORA1 (0.56) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL12015180 | 0.91 | ADORA1 (0.58) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL12646739 | 0.91 | ADORA1 (0.58) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL12590122 | 0.91 | ADORA1 (0.58) | ADORA1ADORA3RNASELP2RY11DNPH1 | |
| SCHEMBL12590112 | 0.91 | ADORA1 (0.54) | ADORA1RNASELP2RY11DNPH1PRKAB2 | |
| SCHEMBL12015170 | 0.91 | ADORA1 (0.54) | ADORA1RNASELP2RY11DNPH1PRKAB2 | |
| SCHEMBL12087504 | 0.91 | ADORA1 (0.54) | ADORA1RNASELP2RY11DNPH1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019172286-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | 第一三共株式会社 | 2019-09-12 | — | — | WO | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2530155-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530154-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530156-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530153-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| EP-2392660-A2 | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor | Matsuo, Masafumi (JP) | 2011-12-07 | — | — | EP | disclosed |
| EP-2386636-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-11-16 | — | — | EP | disclosed |
| EP-2374885-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2135948-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | ADORA1 2617/4885ADORA3 1524/4885RNASEL 7/4885 |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | ADORA1 800/4885ADORA3 725/4885RNASEL 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.